APOB and atherosclerosis: The 2019 European guidelines on lipid management summarized expert consensus as follows: “Given the central causal role of apoB-containing lipoproteins in the initiation and progression of atherosclerosis, direct measurement of the circulating concentration of atherogenic apoB-containing lipoproteins to both estimate risk and guide treatment decisions would be ideal.” [2].